Treatment of poly cystic ovarian syndrome.

A comparison between clinical, metabolic and endocrine effects of n-acetylcystein and metformin in women with poly cystic ovarian syndrome(PCOS).

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201405082624N15

Enrollment

Registered

2014-05-29

Start date

2014-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: N- acetylcystein prescription orally, 600 mg 3 times daily ( totally 1800 mg), for 24 weeks. Intervention 2: Metformin prescription orally,500 mg 3 times daily ( totally 1500 mg),

Treatment - Drugs

N- acetylcystein prescription orally, 600 mg 3 times daily ( totally 1800 mg), for 24 weeks.

Metformin prescription orally,500 mg 3 times daily ( totally 1500 mg), for 24 weeks.

Eligibility

Sex/Gender

Female

Age

20 Years to 36 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 20-36 years old; having poly cystic ovarian syndrome; (Rotterdam society criteria : 2 of 3; having 2 out of 3 criteria including oligo or anovulation, hyperandrogenemia, or hyperandrogenism, poly cystic ovaries in ultrasound). Exclusion criteria: known other systemic and metabolic disorders; congenital adrenal hyperplasia; Cushing syndrome; androgen producing tumors; hyperprolactinemia; hypo or hyper thyroidism; diabetes mellitus; history of peptic ulcer; any other drug use.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change in the menstrual cycle. Timepoint: Monthly. Method of measurement: Data sheets.	—

Secondary

Measure	Time frame
Change in weight. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in body mass index. Timepoint: 24 weeks. Method of measurement: data sheets.;Fasting blood sugar. Timepoint: 24 weeks. Method of measurement: data sheets.;Serum insulin. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in low density lipoprotein. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in HOMA index. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in high density lipoprotein. Timepoint: 24 weeks. Method of measurement: data sheets.	—

Measure

Time frame

Change in weight. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in body mass index. Timepoint: 24 weeks. Method of measurement: data sheets.;Fasting blood sugar. Timepoint: 24 weeks. Method of measurement: data sheets.;Serum insulin. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in low density lipoprotein. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in HOMA index. Timepoint: 24 weeks. Method of measurement: data sheets.;Change in high density lipoprotein. Timepoint: 24 weeks. Method of measurement: data sheets.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Kashanian

Iran University of Medical Sciences

maryamkashanian@yahoo.com+98 21 5563 3244

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026